Diabetic Neuropathy Market Share

  • Report ID: 4526
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT

Diabetic Neuropathy Market Regional Analysis:

North American Market Insights

North America region is set to dominate around 38.8% market share by 2035, driven by rising diabetes prevalence and healthcare expenditure. As per the estimations of the American Diabetes Association in 2018, the total cost of diagnosed diabetes was USD 327 billion of which USD 237 billion was spent on direct medical costs and USD 90 billion on reduced productivity in the U.S. The aged population in the region and the rising concern of people and the government on their health increases the healthcare expenditure in the region. The government also initiated several camps to provide proper awareness and health care to the public. The rising disposable income and increasing penetration of the internet increased the early diagnosis visits in the region is projected to have a positive impact on the diabetic neuropathy market growth during the forecast period. Digitalization and improvement in the infrastructure of hospitals to provide good patient care increases healthcare expenditure and reduces the risk of disease prevalence. All these factors is projected to rise the growth of the global diabetic neuropathy market in the region.

Diabetic Neuropathy Market Share

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of diabetic neuropathy is evaluated at USD 5.12 Billion.

The global diabetic neuropathy market size was worth around USD 4.84 Billion in 2025 and is set to register a CAGR of more than 6.4%, exceeding USD 9 Billion revenue by 2035.

North America diabetic neuropathy market will hold over 38.8% share by 2035, driven by rising diabetes prevalence and healthcare expenditure.

Key players in the market include Hoffmann-La Roche Ltd., Abbott Laboratories, Eli Lilly and Company, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Lupin Limited, Glenmark Pharmaceuticals Limited, Assertio Holdings, Inc., Astellas Pharma US, Inc., Pfizer Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos